Norinchukin Bank The grew its stake in Iqvia Holdings Inc (NYSE:IQV) by 27.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,844 shares of the medical research company’s stock after purchasing an additional 4,544 shares during the quarter. Norinchukin Bank The’s holdings in Iqvia were worth $2,704,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Nomura Asset Management Co. Ltd. raised its position in shares of Iqvia by 1.9% in the third quarter. Nomura Asset Management Co. Ltd. now owns 25,186 shares of the medical research company’s stock valued at $3,268,000 after purchasing an additional 461 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of Iqvia by 19.4% in the second quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 476 shares in the last quarter. IFM Investors Pty Ltd grew its stake in shares of Iqvia by 5.4% in the third quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock valued at $1,205,000 after acquiring an additional 478 shares in the last quarter. State Treasurer State of Michigan grew its stake in shares of Iqvia by 1.0% in the third quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock valued at $6,266,000 after acquiring an additional 500 shares in the last quarter. Finally, Gateway Investment Advisers LLC grew its stake in shares of Iqvia by 9.1% in the third quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock valued at $878,000 after acquiring an additional 563 shares in the last quarter. 93.71% of the stock is currently owned by institutional investors.

In other news, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total value of $46,245,770.10. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Kevin C. Knightly sold 9,216 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $126.46, for a total transaction of $1,165,455.36. The disclosure for this sale can be found here. Insiders have sold 601,586 shares of company stock worth $75,510,422 over the last quarter. Corporate insiders own 6.00% of the company’s stock.

Shares of Iqvia stock opened at $115.44 on Tuesday. The stock has a market cap of $24.15 billion, a price-to-earnings ratio of 23.55, a PEG ratio of 1.71 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $135.48.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.03. The firm had revenue of $2.59 billion for the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, analysts predict that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.

Several research firms recently commented on IQV. Robert W. Baird upped their price target on shares of Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a research note on Tuesday, October 2nd. UBS Group began coverage on shares of Iqvia in a research note on Tuesday, October 9th. They issued a “buy” rating on the stock. Raymond James upped their price target on shares of Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a research note on Friday, August 31st. Argus set a $136.00 price target on shares of Iqvia and gave the company a “buy” rating in a research note on Thursday, August 23rd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $97.00 price target on shares of Iqvia in a research note on Wednesday, July 25th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $133.53.

WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/11/20/iqvia-holdings-inc-iqv-shares-bought-by-norinchukin-bank-the.html.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Initial Public Offering (IPO)

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.